MARKET

SLS

SLS

Sellas Life Sciences Group Inc
NASDAQ
7.08
-0.34
-4.58%
After Hours: 7.15 +0.07 +0.98% 19:57 05/15 EDT
OPEN
7.16
PREV CLOSE
7.42
HIGH
7.47
LOW
6.95
VOLUME
8.55M
TURNOVER
--
52 WEEK HIGH
7.80
52 WEEK LOW
1.360
MARKET CAP
1.32B
P/E (TTM)
-28.7454
1D
5D
1M
3M
1Y
5Y
1D
Weekly Buzz: Lilly Posts Positive Trial Data, Rigel Licenses PROTAC Drug, BMY Strikes $15.2B Deal
NASDAQ · 1d ago
SELLAS Gains Buy Rating as REGAL Milestones Approach and Pipeline Expands; $10 Price Target Reaffirmed
TipRanks · 2d ago
Vishay Intertechnology, Eos Energy Enterprises, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday
Benzinga · 3d ago
SELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline Progresses
Benzinga · 3d ago
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), SELLAS Life Sciences Group (SLS) and Legend Biotech (LEGN)
TipRanks · 3d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 3d ago
At a glance: stocks gapping up premarket
Seeking Alpha · 3d ago
SELLAS rises as Q1 update suggests lead program nears final analysis
Seeking Alpha · 3d ago
More
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.

Webull offers Sellas Life Sciences Group Inc stock information, including NASDAQ: SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLS stock methods without spending real money on the virtual paper trading platform.